Total Funding
73
52
Total FundingGrant raised
Growth Score
-7 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
75208
Emtora Biosciences is a life science company that commercializes a new formulation of an immunosuppressant as a prostate cancer drug.
- Dan Hargrove: CEO
- Mark Horsey: CFO
About the Company
Emtora Biosciences is a life science company that commercializes a new formulation of an immunosuppressant as a prostate cancer drug. The company developing a novel formulation of rapamycin, eRapa for use in preventing the onset and recurrence of cancer. It manufactures a drug to slow the aging process and its efficacy in treating age-related
diseases.
The eRapa is the only pharmaceutical agent to demonstrate significantly increased healthspan and lifespan in rodent models, and Science, Nature, and Time magazines proclaimed the discovery of a special formulation of rapamycin to extend one’s life and health span among the most significant and exciting scientific breakthroughs of 2009.
